News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
ad-hoc-news.de Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
NEKTAR THERAPEUTICS reported Q2 2026 results with revenue of $10.1 million and a net loss of $40.6 million, an improvement from the $41.6 million loss in the prior year. The diluted loss per share was $(1.23). The company highlighted advancements in its pipeline, including …
Nektar Therapeutics announced the initiation of its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis, with top-line data expected in mid-2028 and a potential BLA submission in 2029. The company also finalized plans for a registrational Phase III trial …
Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …
Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …
The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.
Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …
Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …
Nektar Therapeutics is preparing to report second-quarter results, with analysts anticipating a loss of $2.00 per share on revenues of $10.38 million. The report comes as the company launched two pivotal Phase 3 trials for its lead drug candidate, rezpegaldesleukin, drawing investor attention to …
Nektar Therapeutics (NKTR) has experienced significant stock momentum, with year-to-date returns of 75.1% and a 1-year total shareholder return of 195.61%, despite a negative five-year record. The company's stock, currently at $76.03, is considered undervalued by one narrative, with a fair value of $153.25, …
Search by ticker symbol or company name and select a result to open its chart.